THE ALTERNATIVE INVESTMENT AND LENDING SPECIALIST
Asset Manager specialised in :
Alternative fund selection and management
Private market investments
Asset based alternative lending
ITERAM Capital SA is regulated and authorised by FINMA as an Asset Manager of collective investment schemes and as a representative agent of foreign collective investment schemes to qualified investors in Switzerland
EXPERTISE
OVERVIEW
Investment Manager
Advisory & Research Services
Bespoke Solutions
Representative Agent in Switzerland
PRIVATE MARKETS
Privileged access to new sources of alternative income-generating investments and private equity investments, in particular :
real assets (transportation leasing), bridge financing/direct lending, specialty finance (music royalties, litigation funding) and venture capital.
ALTERNATIVE LENDING
Provide innovative structuring and asset backed financing solutions to companies for working capital needs, acquisitions and development.
HEDGE FUNDS
Access to industry’s leading and emerging hedge fund managers, thanks to the team's strong industry network and expertise. Cover all hedge fund investment strategies with a focus on consistent and uncorrelated returns.
LIQUID ALTERNATIVES
Simple way to access alternatives wrapped into liquid vehicles as an alternative solution for investors in need of more regulatory oversight and liquidity.
We provide comprehensive, innovative and customised
alternative investment solutions that address
rapidly changing needs in today’s complex and evolving global markets
OUR VISION
INDEPENDENCE
We are an independent team of investment professionals with a common
interest in dedication to excellence and superior investment returns
INNOVATION
We devote all investment, research and expertise
towards developing a highly specialised investment management
organisation focusing on innovative alternative investment solutions
INTEGRITY
We are committed to deliver full investment transparency to clients.
We developed a cutting edge proprietary asset management system of high quality information and reporting system to support the advisory, research and client services team
INVESTMENT SOLUTIONS
Investment Fund vehicles
Access to actively managed portfolios, concentrated or diversified, across alternative investments via Luxembourg fund structures
e.g.: Absolute Return portfolio, Alternative Income portfolio, Macro Diversified portfolio, Healthcare/Biotech portfolio, Venture Capital portfolio
Co-investments / club deals
Access through a Euroclearable note, listed on a stock-exchange, freely transferable and a bankable ISIN code
e.g.: Equipment Leasing, Direct Lending, Bridge Financing
Bespoke investment solutions
Build your own alternative investment portfolio that best fits your investment goals and risk tolerance
e.g.: Blend of alternative investment strategies
OUR MAIN INVESTMENT STRATEGIES
Private Markets - Direct Investments
Alternative Income Strategy
Access to high income-generating private market assets. Diversified portfolio of strong asset-backed investments with predictable cash flows.
Track Record: 4 years
Performance 2021 YtD Q2: +3.1%
Performance 2020: +7.5%
Performance 2019: +8.9%
Performance 2018: +7.6%
Performance 2017: +5.5%*
Past performance is not indicative of future returns
* Strategy launch date May 31, 2017
For qualified investors only
Private Markets - Venture Capital
Venture Capital Strategy
Access to selected top tier venture capital managers wrapped in a diversified portfolio across stages, sectors, geographies and vintages.
Track Record: 1.5 years
Performance 2021 YtD Q1: +7.2%
Performance 2020: +18.4%*
Past performance is not indicative of future returns
* Strategy launch date January 31, 2020
For qualified investors only
Multi-manager - Uncorrelated
Absolute Return Strategy
Access to the industry’s leading and emerging hedge fund managers wrapped in a unique portfolio composed of various uncorrelated strategies.
Track Record: 15 years
Performance 2021 YtD Q2: +2.3%
Performance 2020: +9.5%
Performance 2019: +8.4%
Performance 2018: +1.0%
Performance 2017: +8.9%
Past performance is not indicative of future returns
For qualified investors only
Multi-manager - Healthcare Biotech
Healthcare Biotech Strategy
Access to the industry’s top leading healthcare and biotech
long/short equity managers, and advised by a scientific and industrial advisory committee.
Track Record: 13 years
Performance 2021 YtD Q2 : -9.5%
Performance 2020: +20.4%
Performance 2019: +29.3%
Performance 2018: +2.2%
Performance 2017: +23.6%
Past performance is not indicative of future returns
For qualified investors only
MEET THE TEAM
The team has a two decades-long institutional expertise and track-record in all fields related to alternative investments. The team was part of the top management in the alternative division at Edmond de Rothschild (Suisse) SA, formerly Banque Privée Edmond de Rothschild, which was the pioneer in alternative multi-management.
The leadership team has high specialisation in different areas comprising investment management, fund selection, structuring, financing, operational due diligence, legal and risk management.
MANUEL GARZELLI
CEO
INVESTMENT MANAGER
Iteram Investments
Edmond de Rothschild
CITCO Finance
MOIRA D'ANTERROCHES
ODD / CONTROLLER MANAGER
Nestlé Capital Advisers
Lloyds Banking
Lehman Brothers, Natixis
MARC SBEGHEN
CFO / FUND RESEARCH
INVESTMENT MANAGER
PvB Pernet von Ballmoos AG
Edmond de Rothschild
Banque Cantonale de Genève
MAROUANE DAHO
INVESTMENT ANALYST
RESEARCH
Lera Capital
Lyxor Asset Management
Credit Agricole CIB
ALEXANDRE LOUCHTCHAY
CRO
RISK MANAGER
Edmond de Rothschild
EDRAM (France)
DEBORA LETTIERI
OPERATIONS / ADMIN MANAGER
Edmond de Rothschild
Credit Suisse
OREN PINSKY
VENTURE CAPITAL ADVISOR
Qualcomm
Stratus Group
McKinsey & Co
JAUME SABATER
VICE CHAIRMAN
OF THE BOARD
Stoneweg SA
Edmond de Rothschild
Universal Gestio
AMBROISE MAGISTRETTI
HEALTHCARE BIOTECH ADVISOR
Seveneast Healthcare
GliaPharm
MindMaze
JEAN-YVES REBORD
NON-EXECUTIVE
BOARD MEMBER
Python Avocats
Baker & McKenzie
Credit Suisse
YVES CLAUDE AUBERT
CHAIRMAN
OF THE BOARD
Independent director
Banque Cantonale Vaudoise
LAURENT AUCHLIN
NON-EXECUTIVE
BOARD MEMBER
Anglo-Swiss Advisors
Credit Suisse
Lombard Odier
INSIGHTS & NEWS
February 2021
News article
Allocators Outside of the U.S. Unfurl Their Top Investing Ideas
European-based global allocators spy select opportunity in developed markets, value stocks, and Asian emerging markets amid a global recovery. Marc Sbeghen, cofounder and head of fund research, outlines where he sees compelling opportunities in the market.
January 2021
Allnews.ch - Interview
Spécialiste genevois des placements alternatifs
L’objectif d’ITERAM est d’offrir un accès facilité, différencié et de qualité. Entretien avec Manuel Garzelli, associé et CEO.
January 2021
Alternative flash update
Some Hedge Funds caught off guard
Hedge Fund managers takeaways
#alternative investments #hedgefunds #riskadjustedreturns #uncorrelated
PRESS RELEASE
January 2021
ALTERNATIVE SPECIALIST, ITERAM CAPITAL, GRANTED ASSET MANAGER LICENCE
GENEVA, Switzerland, Jan. 13, 2021 -- ITERAM Capital SA, an independent alternative investment company, is pleased to announce that it has been authorized by the Swiss Financial Market Supervisory Authority (FINMA) as an authorized asset manager of collective investment schemes. This new licence is an addition to the company's current licence of providing representation services for foreign collective investment schemes to qualified investors in Switzerland received in 2017. With these two authorizations, ITERAM aims to become a leading alternative asset manager player covering private markets, hedge funds, and liquid fund alternatives.
November 2020
HFM Award - shortlisted
Thrilled to announce that the Alternative Income strategy made it to the final shortlist of Top performing funds for the HFM Global EuroHedge Emerging Manager Awards 2020 in the Specialist Finance category held on November 17, 2020.
The HFM EuroHedge Emerging Manager Awards will honour the best performing and recently launched hedge funds in Europe. Nominees will have proven themselves capable of outperformance in the hardest of circumstances.
Q3 2020
Alternative Causerie
Alternative investments performance and opportunities
SPAC's in the spotlight amid pandemic
Covid-19 impact on due diligence
2020
Strategy anniversary
Celebrating 3 years of track record with a successful +8.3% net annualised return to investors. Private Markets investments offer investors attractive risk-adjusted returns and diversified sources of returns.
#privatemarkets #alternativeincome #riskadjustedreturns #uncorrelated #multisector #realassets #bridgefinancing #specialtyfinance
June 2020
HFR European Awards
For the second year in a row, ITERAM Capital is pleased to announce a double-win for the Healthcare Biotech strategy, at the “Hedge Funds Review - European Performance Awards 2020”. The Healthcare Biotech strategy was awarded the best sub-$100M specialist fund of hedge funds over 5 years and 10 years.
May 2020
Performance
Ready to enhance and expand your portfolio with Alternatives?
ITERAM offers investors access to well needed alternative investments toolkit with strong risk-adjusted returns
#alternativeinvestments #hedgefunds #privatemarkets #uncorrelated
March 2020
Private Markets - Income
Looking for innovative sources of income? Benefit from a unique and uncorrelated Private Markets investment solution that delivered +8.9% net return to investors in 2019 and +8.6% annualised return since inception in May 2017. Diversified portfolio of direct investments with predictable cash flows and high asset-collateral coverage.
March 2020
Flash Update #2: Covid-19
The financial meltdown worst days since 1987
Hedge Funds protecting on the downside
A new Dawn for Alternatives
January 2020
New Board Member
ITERAM Capital is pleased to announce the appointment of Dr. Jean-Yves Rebord, an experienced attorney in Banking and Finance, as a member of the Board of Directors. Jean-Yves will significantly strengthen the regulatory and corporate governance of the firm.
January 2020
Performance
2019 was yet another successful year with solid risk-adjusted returns to investors crowned with prestigious award recognitions!
Is your portfolio ready for the next decade?
Q4 2019
Alternative Causerie
2019 Markets review
Hedge Funds as a diversification tool
Private Markets goes mainstream
December 2019
Award - Winner
Healthcare Biotech strategy
Best sub-$100M specialist fund of hedge funds over 5 and 10 years
November 2019
Award - Winner
Absolute Return strategy
Best FoHF multi-strategy defensive bias over 3 years
OUR ADDRESS
Boulevard Georges-Favon 8
1204 Geneva - Switzerland
